The Medtech Crucible: EBR Systems Taps Clinician for WiSE Rollout

SUNNYVALE, Calif. – October 20, 2026 – The architecture of modern healthcare is often designed in corporate boardrooms, but its structural integrity is ultimately tested at the patient’s bedside. In the high-stakes ecosystem of medical technology, the transition from regulatory triumph to commercial reality is a perilous bridge to cross. This week, EBR Systems, Inc. signaled its strategy for navigating that crossing by appointing Dr. Robert C. Canby, a practicing board-certified cardiac electrophysiologist, as its new Chief Medical Officer.

Dr. Canby succeeds Dr. Spencer Kubo, who is retiring from the industry after successfully steering the company’s flagship WiSE System through the pivotal SOLVE-CRT trial and securing a hard-won Premarket Approval from the U.S. Food and Drug Administration in April 2025. But where Dr. Kubo’s mandate was validation, Dr. Canby’s mandate is adoption.

Crucially, Dr. Canby is not leaving his day job. He will maintain his active clinical practice at the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas, and continue serving as President of the Texas Cardiac Arrhythmia Research Foundation. Working on the company's behalf as his other duties permit, this dual-role structure places a clinician with his hands still on the instruments at the helm of the company's medical strategy.

"Dr. Canby is a highly respected cardiac electrophysiologist and brings an exceptional combination of clinical expertise, medical device experience and a deep understanding of cardiac electrophysiology," said John McCutcheon, President and Chief Executive Officer of EBR Systems. "His perspective as a practicing physician will be invaluable as we scale adoption of the WiSE System and continue our clinical development programs."

For Dr. Canby, the appeal lies in scaling the impact of a device he already utilizes. "I am excited to take on the role of EBR Systems’ CMO," he noted in the company's announcement. "I have always been interested in the intersection of technology and better clinical outcomes for our patients. I have seen firsthand the benefit that EBR’s technology has brought to my patients, and I hope that in this new role I can help impact even more patients. This particular technology is so important as it provides physicians with an important tool to treat patients that might otherwise not receive optimal therapy."

The Next Frontier in Cardiac Resynchronization

To understand the significance of this executive shift, one must understand the mechanical failure it seeks to address. Heart failure remains one of the most intractable public health challenges of our time. For decades, standard Cardiac Resynchronization Therapy has relied on transvenous leads—wires threaded through the venous system to pace the heart and correct its uncoordinated beating.

Yet, the structural limitations of conventional therapy are glaring. Up to 30 percent of patients simply do not respond to the treatment. Another 5 to 10 percent are deemed entirely untreatable due to anatomical challenges, chronic lead failures, or the high procedural risks of placing a lead in the coronary sinus.

The WiSE System was engineered specifically for these populations—the previously untreatable and those requiring high-risk upgrades. As the world’s first and only FDA-approved system for leadless left ventricular endocardial pacing, it abandons the wire entirely. Instead, a subcutaneous transmitter detects the right ventricular pacing signal and, within milliseconds, beams targeted ultrasound energy to a rice-sized electrode implanted directly inside the left ventricle. This electrode converts the acoustic energy into an electrical pulse, achieving synchronized biventricular pacing without the physical vulnerabilities of a transvenous lead.

The broader leadless pacemaker market is expanding rapidly, projected to grow at a compound annual growth rate of nearly 10 percent to reach over $1 billion by 2034. While giants like Medtronic and Abbott dominate the single-chamber leadless pacemaker space with devices like the Micra and Aveir, the WiSE System occupies a unique, complementary niche. In fact, the device is designed to work in tandem with these competitors; the Medtronic Micra is already qualified for use with the system, and testing is currently underway for compatibility with the Abbott Aveir. This interoperability is crucial for patients who already have a right ventricular leadless pacemaker but require an upgrade to biventricular pacing.

The regulatory and financial frameworks surrounding the device have rapidly solidified. Following its April 2025 FDA approval, the Centers for Medicare & Medicaid Services granted the system crucial New Technology Add-on Payment and Transitional Pass-Through designations. By October 1, 2026, the company secured a substantial victory when Medicare inpatient payment rates for eligible procedures increased by up to 93 percent, potentially bringing total Medicare inpatient reimbursement to over $77,000 per procedure.

Commercial Realities and Clinical Friction

Despite these regulatory and reimbursement tailwinds, the commercial rollout of a paradigm-shifting medical device is rarely frictionless. The appointment of an active clinician to the CMO role comes at a critical juncture for the Sunnyvale-based company as it navigates the complex realities of mainstream medical adoption.

The company initiated a limited market release in late 2025 before a full-scale launch in early 2026. Initial traction was promising. In the first quarter of 2026, the company reported 41 commercial implants and $2.36 million in revenue, expanding into major hospital networks like HCA Healthcare and Advocate Health. The second quarter saw 46 implants.

However, preliminary data for the third quarter of 2026 indicates a dip to 40 implants—a figure below the company’s prior forecasts. This deceleration has been attributed to a commercial leadership transition, the rollout of a refocused commercial strategy prioritizing deeper utilization within existing accounts rather than broad expansion, and the necessity for rigorous, ongoing field training.

More pressing are the inherent clinical complexities of the technology itself. In July 2026, the company disclosed a serious adverse event involving a patient death, alongside serious morbidity in another patient, in the context of system implants. These events triggered an FDA review process and highlighted the delicate interplay between novel wireless endocardial pacing and standard hospital protocols.

Because the device relies on acoustic energy, it can be sensitive to external interference. The company recently had to develop and disseminate specific echocardiography guidelines, as certain high-intensity ultrasound imaging procedures have the potential to cause inappropriate heart stimulation by interacting with the implanted receiver.

"When you introduce a fundamentally new energy modality into the human body, the learning curve extends far beyond the initial implant procedure," noted one independent medtech market analyst. "You are retraining the entire hospital ecosystem—from the electrophysiologists to the echocardiography technicians. Having a CMO who is actively navigating those exact hospital protocols in his own practice is a strategic necessity, not just a public relations move."

Bridging the Bedside and the Boardroom

This brings us to the structural dynamic of the dual-role Chief Medical Officer. In the medical device industry, appointing a practicing physician to a corporate leadership role is a recognized strategy to bridge the chasm between engineering theory and clinical reality.

Dr. Canby’s continued presence at the Texas Cardiac Arrhythmia Institute serves a dual purpose. First, it ensures that the company's medical strategy—including evidence development and physician education—is continuously informed by real-world bedside experience. He understands the operational friction of introducing new technologies into a busy electrophysiology lab because he lives it every single day.

Second, it provides a vital layer of peer-to-peer credibility. Electrophysiologists are notoriously data-driven and cautious; they are far more likely to trust clinical guidance from a colleague who shares their daily operational risks than from a full-time corporate executive isolated from patient care.

Naturally, this model requires rigorous navigation of institutional governance. The modern healthcare system is acutely sensitive to conflicts of interest, requiring strict adherence to transparency protocols, such as the CMS Open Payments database, to ensure that financial relationships do not improperly influence clinical decision-making. By explicitly outlining Dr. Canby's ongoing clinical commitments, the company is leaning into the transparency required to make this dual-role structure viable and ethical.

Ultimately, the integration of the WiSE System into standard cardiac care represents a broader theme in the evolution of public health infrastructure. We are witnessing a shift where the physical hardware of medical intervention—the wires and leads that have defined pacing for half a century—is being replaced by invisible, acoustic, and digital networks. As this technology scales, the burden of proof shifts from the controlled environment of a clinical trial to the unpredictable realities of the public square. By placing an active physician at the intersection of policy, technology, and patient care, the company is betting that the best way to secure the structural integrity of its innovation is to keep its leadership firmly grounded in the clinic.